Tiziana Life Sciences Plc - Company Profile
Powered by
All the data and insights you need on Tiziana Life Sciences Plc in one report.
- Save hours of research time and resources with
our up-to-date Tiziana Life Sciences Plc Strategy Report
- Understand Tiziana Life Sciences Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences Plc, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company's other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in London, the UK.
Tiziana Life Sciences Plc premium industry data and analytics
Products and Services
Products |
---|
Pipeline: |
Clinical Programmes |
Milciclib - Thymic Carcinoma |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Tiziana Life Sciences Plc | BioNTech SE | Iovance Biotherapeutics Inc | Celgene Corp | Juno Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United Kingdom | Germany | United States of America | United States of America | United States of America |
City | Hamilton | Mainz | San Carlos | Summit | Seattle |
State/Province | South Lanarkshire | Nordrhein-Westfalen | California | New Jersey | Washington |
No. of Employees | 9 | 6,133 | 557 | - | 533 |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gabriele Marco Antonio Cerrone | Chief Executive Officer - Acting; Chairman | Executive Board | 2022 | 51 |
Keeren Shah | Chief Financial Officer | Senior Management | 2020 | - |
Matthew W. Davis, MD | Chief Medical Officer; Chief Operating Officer | Senior Management | 2023 | - |
William A. Clementi | Chief Development Officer | Senior Management | 2023 | - |
Vaseem A. Palejwala, Ph.D. | Senior Director-Clinical Operations | Senior Management | 2022 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer